Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Evaluation of HepaGam B™ in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients

Study:

Evaluation of HepaGam B™ in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients

Rationale:

n/a

Purpose:

The purpose of the study is to assess the pharmacokinetics, safety and efficacy of HepaGam B in combination with antiviral therapy for the prevention of hepatitis B virus (HBV) recurrence following HBV-related orthotopic liver transplant.

Study Status: Recruiting

Recruiting:
n/a

Condition Intervention Phase
Hepatitis B
Liver Transplantation		 Biological: HepaGam B Phase 4

Verified by Cangene Corporation September, 2008

Sponsored by: Cangene Corporation
Information provided by: Cangene Corporation
ClinicalTrials.gov identifier: NCT00722332

Study Type: Interventional

Study Design: Prevention, Open Label, Single Group Assignment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.